Rani Therapeutics Holdings (RANI) Return on Capital Employed (2021 - 2026)
Rani Therapeutics Holdings (RANI) posted quarterly Return on Capital Employed of 83.67% for Q1 2026, up 41678.0% year-over-year from N/an in Q1 2025, and up 52.58% quarter-over-quarter from 176.45% in Q4 2025.
Rani Therapeutics Holdings (RANI) Return on Capital Employed (2021 - 2026) Analysis & Trends
Rani Therapeutics Holdings' Return on Capital Employed history runs 6 years deep, the most recent figure standing at 83.67% for Q1 2026.
- In Q1 2026, Return on Capital Employed rose 41678.0% year-over-year to 83.67%; the TTM figure through Mar 2026 stood at 83.67% (up 41678.0% YoY), while the FY2025 annual figure was 109.59%, up 8510.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 83.67%, up from 176.45% in the prior quarter.
- The five-year high for Return on Capital Employed was 44192.83% in Q2 2025, with the low at 500.45% in Q1 2025.
- The 5-year median for Return on Capital Employed is 83.67% (2026), against an average of 2517.79%.
- Peak annual rise in Return on Capital Employed reached 4437338 bps in 2025, while the deepest fall reached 35020 bps in 2025.
- Rani Therapeutics Holdings' Return on Capital Employed stood at 61.42% in 2022, then slumped by 92 bps to 117.64% in 2023, then plunged by 124 bps to 263.99% in 2024, then surged by 33 bps to 176.45% in 2025, then soared by 53 bps to 83.67% in 2026.
- Business Quant data shows RANI's Return on Capital Employed at 83.67% in Q1 2026, 176.45% in Q4 2025, and 795.18% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.60 Bn | 130.75 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.93 Bn | 77.93 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 65.06 Bn | 59.88 Bn | 1.37 Bn | - |
| 4 | Moderna | 56.22 Bn | 51.08 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 42.03 Bn | 36.93 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.65 Bn | 28.34 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 27.70 Bn | 9.31 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.31 Bn | 26.48 Bn | - | 7.88% |
| 10 | Rani Therapeutics Holdings | 162.31 Mn | 162.31 Mn | - | -72.08% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -72.08% |
| Mar 31, 2026 | -83.67% |
| Dec 31, 2025 | -176.45% |
| Sep 30, 2025 | 795.18% |
| Jun 30, 2025 | 44,192.83% |
| Mar 31, 2025 | -500.45% |
| Dec 31, 2024 | -263.99% |
| Sep 30, 2024 | -221.12% |
| Jun 30, 2024 | -180.56% |
| Mar 31, 2024 | -150.26% |
| Dec 31, 2023 | -117.64% |
| Sep 30, 2023 | -100.75% |
| Jun 30, 2023 | -81.47% |
| Mar 31, 2023 | -68.17% |
| Dec 31, 2022 | -61.42% |
| Sep 30, 2022 | -59.88% |
| Jun 30, 2022 | -67.74% |
| Mar 31, 2022 | -52.06% |
| Dec 31, 2021 | -40.33% |
| Sep 30, 2021 | -42.38% |